EGFR and non-small cell lung carcinoma: While clinical trials have shown the activity of HSP90 inhibitors in NSCLC patients harboring EGFR mutations,25, 26 whether inhibition of HSP90 can overcome acquired resistance to third‐generation EGFR‐TKIs remains to be determined.